Werewolf Therapeutics (HOWL) Change in Account Payables (2020 - 2023)
Werewolf Therapeutics (HOWL) posted quarterly Change in Account Payables of -$104000.0 for Q3 2023, up 88.57% year-over-year from -$55151.5 in Q3 2022, and up 83.12% on a QoQ basis from -$616000.0 in Q2 2023.
Werewolf Therapeutics (HOWL) Change in Account Payables (2020 - 2023) Analysis & Trends
Werewolf Therapeutics has reported Change in Account Payables for 4 years, with the latest figure at -$104000.0 in Q3 2023.
- Change in Account Payables for Q3 2023 came in at -$104000.0, up 88.57% year-over-year; the trailing twelve-month figure through Sep 2023 was $136000.0 (up 207.09% YoY), and the FY2022 annual result was -$883000.0, down 187.69% from the prior year.
- Change in Account Payables grew to -$104000.0 in Q3 2023, from -$616000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $1.1 million in Q2 2021 and troughed at -$1.5 million in Q3 2021.
- A 4-year average of $50200.0 and a median of $276000.0 in 2020 frame the typical range for Change in Account Payables.
- The largest YoY upside for Change in Account Payables was 313.04% in 2021 against a maximum downside of 530.86% in 2021.
- A 4-year view of Change in Account Payables shows it stood at -$540000.0 in 2020, then jumped by 220.56% to $651000.0 in 2021, then sank by 116.13% to -$105000.0 in 2022, then rose by 0.95% to -$104000.0 in 2023.
- Per Business Quant data, the three most recent Change in Account Payables figures were -$104000.0 in Q3 2023, -$616000.0 in Q2 2023, and $961000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Werewolf Therapeutics | 43.94 Mn | 43.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -104,000.00 |
| Sep 30, 2023 | -104,000.00 |
| Jun 30, 2023 | -616,000.00 |
| Jun 30, 2023 | -616,000.00 |
| Mar 31, 2023 | 961,000.00 |
| Mar 31, 2023 | 961,000.00 |
| Dec 31, 2022 | -105,000.00 |
| Dec 31, 2022 | -105,000.00 |
| Sep 30, 2022 | -910,000.00 |
| Sep 30, 2022 | -910,000.00 |
| Jun 30, 2022 | 806,000.00 |
| Jun 30, 2022 | 806,000.00 |
| Mar 31, 2022 | -674,000.00 |
| Mar 31, 2022 | -674,000.00 |
| Dec 31, 2021 | 651,000.00 |
| Dec 31, 2021 | 651,000.00 |
| Sep 30, 2021 | -1.51 Mn |
| Sep 30, 2021 | -1.51 Mn |
| Jun 30, 2021 | 1.14 Mn |
| Jun 30, 2021 | 1.14 Mn |